XML 48 R37.htm IDEA: XBRL DOCUMENT
v3.24.3

Revenue Recognition - Collaboration and License Agreement (Details) |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 46 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Nov. 22, 2020 USD ($) program obligation target | Dec. 31, 2022 USD ($) | Nov. 30, 2020 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2024 USD ($) program | Sep. 30, 2023 USD ($) | Sep. 30, 2024 USD ($) | Dec. 31, 2023 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue, revenue recognized |  |  |  | $ 16,959,000 | $ 25,439,000 | $ 45,199,000 | $ 55,807,000 |  |
Total revenues |  |  |  | 35,290,000 | 42,569,000 | $ 119,222,000 | 142,540,000 |  |
BMS | Collaboration and License Agreement |  |  |  |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |  |  |
Number of biological targets | target | 5 |  |  |  |  |  |  |  |
Number of wholly owned programs | program | 2 |  |  |  |  |  |  |  |
Number of oncology targets | program | 2 |  |  |  |  |  |  |  |
Number of programs under agreement | program | 5 |  |  |  |  | 1 |  |  |
Upfront fee received |  | $ 55,000,000.0 | $ 55,000,000.0 |  |  |  |  |  |
Maximum milestone payments to be received | $ 482,000,000.0 |  |  |  |  |  |  |  |
Number of remain milestone payment targets | target | 1 |  |  |  |  |  |  |  |
Number of performance obligations | obligation | 1 |  |  |  |  |  |  |  |
Transaction price | $ 55,000,000.0 |  |  |  |  |  |  |  |
Total revenues |  |  |  | 1,100,000 | $ 11,200,000 | $ 10,100,000 | $ 40,000,000.0 |  |
Deferred revenue |  |  |  | 3,600,000 |  | 3,600,000 |  | $ 3,600,000 | $ 7,300,000
Receivable from collaboration |  |  |  | $ 0 |  | $ 0 |  | 0 | $ 0
BMS | Collaboration and License Agreement | Neurology and Immunology Product |  |  |  |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |  |  |
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones | 257,000,000.0 |  |  |  |  |  |  |  |
Milestone payments to be received upon achievement of certain specified commercial milestones | $ 225,000,000.0 |  |  |  |  |  |  |  |
BMS | Collaboration and License Agreement | Oncology, Neurology, and Immunology Product |  |  |  |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue, revenue recognized |  |  |  |  |  |  |  | $ 32,000,000.0 |

X
- Definition Collaboration and license agreement transaction price. + References No definition available. + Details
Name: | sdgr_CollaborationAndLicenseAgreementTransactionPrice
Namespace Prefix: | sdgr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative agreement number of programs. + References No definition available. + Details
Name: | sdgr_CollaborativeAgreementNumberOfPrograms
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum milestone payments to be received. + References No definition available. + Details
Name: | sdgr_MaximumMilestonePaymentsToBeReceived
Namespace Prefix: | sdgr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payments to be received upon achievement of certain specified commercial milestones. + References No definition available. + Details
Name: | sdgr_MilestonePaymentsToBeReceivedUponAchievementOfCertainSpecifiedCommercialMilestones
Namespace Prefix: | sdgr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones. + References No definition available. + Details
Name: | sdgr_MilestonePaymentsToBeReceivedUponAchievementOfCertainSpecifiedResearchDevelopmentAndRegulatoryMilestones
Namespace Prefix: | sdgr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number Of Biological Targets + References No definition available. + Details
Name: | sdgr_NumberOfBiologicalTargets
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Oncology Programs + References No definition available. + Details
Name: | sdgr_NumberOfOncologyPrograms
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Performance Obligations + References No definition available. + Details
Name: | sdgr_NumberOfPerformanceObligations
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Remain Milestone Payment Targets + References No definition available. + Details
Name: | sdgr_NumberOfRemainMilestonePaymentTargets
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Wholly Owned Programs + References No definition available. + Details
Name: | sdgr_NumberOfWhollyOwnedPrograms
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Receivable from collaboration. + References No definition available. + Details
Name: | sdgr_ReceivableFromCollaboration
Namespace Prefix: | sdgr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | sdgr_UpfrontPaymentReceived
Namespace Prefix: | sdgr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sdgr_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sdgr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sdgr_NeurologyAndImmunologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sdgr_OncologyNeurologyAndImmunologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |